This observation led to the development of a humanised anti-VEGF monoclonal antibody, bevacizumab, which has shown an improved progression-free survival benefit in numerous tumour types (Hurwitz et al, 2004; Miller et al, 2007; Rini et al, 2010). This evidence concerns the gene VEGFA and neoplasm.